Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Canopy Growth CorporationNASDAQ: CGC

Income Tax Expense · Q4 FY2025 · quarter ended Mar 2026

Income tax expense turns negative

Q4 FY2025 income tax expense was -CA$850K, compared with CA$329K a year earlier. Trailing-twelve-month income tax expense was CA$159.94K.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, down 2.6 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near -CA$850K or moves back toward the trailing-twelve-month quarterly average of CA$39.99K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$850K-268.3% QoQ
Last fiscal yearMar 2026
CA$23K-99.7% YoY
LTMMar 2026
CA$159.94K-97.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-358.4%——
1 year-99.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

CAD · from the income statement

Latest · FY2025
23K CAD
Year-over-year change
-99.7%

Income Tax Expense vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.8% is the lowest of 5, against a peer median of +59.1%.
  • Income tax expense amounts to 0.1% of revenue for CGC, versus a peer median of 0.3%.
CGC Competitors
Income Tax Expense for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$69.29M USD+23.1%-15.9%19.2%
ACBAurora Cannabis Inc.LTM Mar 2026CA$2.93M CAD-36.6%-49.7%0.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$413K USD——0.3%
CGCCanopy Growth CorporationLTM Mar 2026CA$159.94K CAD-97.8%—0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$83K USD+359.4%—0.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 USD——0.0%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
BIOABioAge Labs, Inc.LTM Mar 2026$0 USD——0.0%
DHDefinitive Healthcare Corp.LTM Mar 2026-$2.51M USD+95.2%—1.1%
Peer median (excluding CGC) —+59.1%-32.8%0.3%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.